» Articles » PMID: 33857070

State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose - United States, 2017

Overview
Date 2021 Apr 15
PMID 33857070
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Approximately 47,000 persons in the United States died from an opioid-involved overdose in 2018 (1), and 2.0 million persons met the diagnostic criteria for an opioid use disorder in 2017 (2). The economic cost of the U.S. opioid epidemic in 2017 was estimated at $1,021 billion, including cost of opioid use disorder estimated at $471 billion and cost of fatal opioid overdose estimated at $550 billion (3). CDC used national-level cost estimates to estimate the state-level economic cost of opioid use disorder and fatal opioid overdose during 2017. Cases and costs of state-level opioid use disorder and fatal opioid overdose and per capita costs were calculated for each of the 38 states and the District of Columbia (DC) that met drug specificity requirements for mortality data (4). Combined costs of opioid use disorder and fatal opioid overdose (combined costs) varied substantially, ranging from $985 million in Wyoming to $72,583 million in Ohio. Per capita combined costs also varied considerably, ranging from $1,204 in Hawaii to $7,247 in West Virginia. States with high per capita combined costs were mainly in two regions: the Ohio Valley and New England. Federal and state public health agencies can use these data to help guide decisions regarding research, prevention and response activities, and resource allocation.

Citing Articles

Buprenorphine's Effect on the Human Immune System and Inflammation.

Shin S, Branning R, McGinnis M, Shin A, Ho M, Karpyak V Clin Transl Sci. 2025; 18(3):e70180.

PMID: 40065582 PMC: 11893730. DOI: 10.1111/cts.70180.


Hospital and physician-based mental healthcare during 12 months of opioid agonist treatment for opioid use disorder: Exploring costs and factors associated with acute care.

Rosic T, Babe G, Rodrigues M, Dennis B, Perez R, de Oliveira C PLoS One. 2025; 20(1):e0314296.

PMID: 39775273 PMC: 11709258. DOI: 10.1371/journal.pone.0314296.


Impact of neighborhood-level COVID-19 mortality on the increase in drug overdose mortality in New York City during the COVID-19 pandemic.

Olawole W, Li G, Zhou Z, Wu Z, Chen Q Inj Epidemiol. 2024; 11(1):65.

PMID: 39578923 PMC: 11585137. DOI: 10.1186/s40621-024-00548-8.


The Nexus of Aging and Substance Use: A Scoping Review of Therapeutic Modalities for Geriatric Substance Use Disorders.

Leton N Cureus. 2024; 16(9):e70313.

PMID: 39463556 PMC: 11512750. DOI: 10.7759/cureus.70313.


Impact of California's naloxone co-prescription law on emergency department visits, 30-day mortality, and prescription patterns.

Ghobadi A, Hanna M, Tovar S, Do D, Duan L, Lee M J Am Coll Emerg Physicians Open. 2024; 5(5):e13236.

PMID: 39430661 PMC: 11486842. DOI: 10.1002/emp2.13236.


References
1.
Dowell D, Zhang K, Noonan R, Hockenberry J . Mandatory Provider Review And Pain Clinic Laws Reduce The Amounts Of Opioids Prescribed And Overdose Death Rates. Health Aff (Millwood). 2016; 35(10):1876-1883. PMC: 6583870. DOI: 10.1377/hlthaff.2016.0448. View

2.
Luo F, Florence C . State-Level Lifetime Medical and Work-Loss Costs of Fatal Injuries - United States, 2014. MMWR Morb Mortal Wkly Rep. 2017; 66(1):1-11. PMC: 5687268. DOI: 10.15585/mmwr.mm6601a1. View

3.
Wilson N, Kariisa M, Seth P, Smith 4th H, Davis N . Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018. MMWR Morb Mortal Wkly Rep. 2020; 69(11):290-297. PMC: 7739981. DOI: 10.15585/mmwr.mm6911a4. View

4.
Florence C, Luo F, Rice K . The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2020; 218:108350. PMC: 8091480. DOI: 10.1016/j.drugalcdep.2020.108350. View

5.
Walley A, Xuan Z, Hackman H, Quinn E, Doe-Simkins M, Sorensen-Alawad A . Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013; 346:f174. PMC: 4688551. DOI: 10.1136/bmj.f174. View